Analyst consensus rating
AnaptysBio Analyst Rating: Strong Buy
ANAB is rated Strong Buy by 11 analysts with a $86.64 target. As of 2026-08-30.
Direct answer
AnaptysBio's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $86.64.
Forecast evidence checked August 30, 2026.
Get free AnaptysBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $56.28
- Average price target
- $86.64
- High price target
- $140.00
- Low price target
- $70.00
- Low target gap
- +24.4%
- Target upside
- +53.9%
- High target gap
- +148.8%
- Target range width
- 124.4%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AnaptysBio?
AnaptysBio has a verified Strong Buy consensus. The same dataset has an average price target of $86.64.
How far are AnaptysBio's low and high targets from the recorded price?
The low target implies +24.4%, while the high target implies +148.8%.
How many analysts are included in AnaptysBio's consensus?
The verified consensus includes 11 analysts.
How is AnaptysBio's target upside or downside calculated?
The average target of $86.64 is divided by the recorded price of $56.28, then one is subtracted to produce +53.9%. This does not guarantee a future return.
When was AnaptysBio's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.